Anika Therapeutics, Inc. (ANIK)
Market Cap | 253.81M |
Revenue (ttm) | 164.17M |
Net Income (ttm) | -97.52M |
Shares Out | 14.65M |
EPS (ttm) | -6.62 |
PE Ratio | n/a |
Forward PE | 41.26 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 90,401 |
Open | 17.87 |
Previous Close | 17.87 |
Day's Range | 17.19 - 18.17 |
52-Week Range | 16.00 - 29.12 |
Beta | 0.90 |
Analysts | Buy |
Price Target | 24.50 (+41.37%) |
Earnings Date | Oct 31, 2024 |
About ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from... [Read more]
Financial Performance
In 2023, Anika Therapeutics's revenue was $166.66 million, an increase of 6.67% compared to the previous year's $156.24 million. Losses were -$82.67 million, 456.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 41.37% from the latest price.
News
Anika To Participate in December 2024 Investor Conferences
BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management...
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - Presiden...
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
WEST BRIDGEWATER, Mass. , Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoratio...
Anika Reports Third Quarter 2024 Financial Results
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwin...
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitab...
Anika Announces Third Quarter 2024 Results Conference Call Date
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 202...
Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript
Anika Therapeutics, Inc (NASDAQ:ANIK) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Ex...
Anika Reports Second Quarter 2024 Financial Results
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating signif...
Anika to Participate in the Sidoti Virtual Investor Conference
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will p...
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research
Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerati...
Anika Enters into Cooperation Agreement with Caligan Partners
Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communicati...
Anika Announces CFO Transition
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024
Anika Reports First Quarter 2024 Financial Results
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million,...
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plan...
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will ...
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reductio...
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
Announcing the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
Integrity marks Anika's entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio
Anika to Participate in Upcoming Investor Conferences
BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanch...